A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Clinical trial NCT06710288 · RECRUITING

Trial details

NCT number: NCT06710288
Sponsor: ImmunityBio, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Platinum-resistant Ovarian Cancer

Start date: 2024-11-06
Primary completion: 2027-05-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.